Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
View Patent ↗The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
1. A crystalline Form N-1 of
characterized by the following unit cell parameters:
Cell dimensions:
a=8.4299(4) Å
b=6.0698(3) Å
c=19.0689(12) Å
alpha=90°
beta=100.169(2)°
gamma=90°
Space group Monoclinic, P2 1
Volume 960.39(9) Å 3
Z, Calculated density 2, 1.267 g/cm 3 .
wherein measurement of said crystalline form is at a temperature between about 20° C. to about 25° C.
2. The crystalline Form N-1 according to claim 1 , characterized by fractional atomic coordinates within the unit cell as listed in Table 3.
3. The crystalline Form N-1 according to claim 1 , characterized by a melt with decomposition endotherm with onset typically in the range of 235-245° C.
4. The crystalline Form N-1 according to claim 1 , wherein said Form N-1 has a purity of at least 98 weight percent.
5. The crystalline Form N-1 according to claim 1 , wherein said Form N-1 has a purity of at least 99 weight percent.
6. A pharmaceutical composition comprising crystalline Form N-1 according to claim 1 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising crystalline Form N-1 according to claim 1 in combination with one or more additional drugs.